

# Long-term cysteine fortification impacts cysteine/glutathione homeostasis and food intake in ageing rats

Karine Vidal, Denis Breuillé, Patrick Serrant, Philippe Denis, Francoise Glomot, Fabienne Bechereau, Isabelle Papet

### ▶ To cite this version:

Karine Vidal, Denis Breuillé, Patrick Serrant, Philippe Denis, Francoise Glomot, et al.. Long-term cysteine fortification impacts cysteine/glutathione homeostasis and food intake in ageing rats. European Journal of Nutrition, 2014, 53 (3), pp.963 - 971. 10.1007/s00394-013-0600-0. hal-02634675

## HAL Id: hal-02634675 https://hal.inrae.fr/hal-02634675v1

Submitted on 27 May 2020  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

#### Long-term cysteine fortification impacts cysteine/glutathione homeostasis and food intake in ageing rats

Karine Vidal,<sup>1</sup> Denis Breuillé,<sup>1</sup> Patrick Serrant,<sup>1</sup> Philippe Denis,<sup>2,3</sup> Françoise Glomot,<sup>2,3</sup> Fabienne Béchereau,<sup>2,3</sup> Isabelle Papet<sup>2,3,\*</sup>

<sup>1</sup> Department of Nutrition and Health, Nestlé Research Center, CH-10000 Lausanne 26, Switzerland, <sup>2</sup> INRA, UMR 1019, UNH, CRNH Auvergne, F-63000 CLERMONT-FERRAND and <sup>3</sup> Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, BP 10448, F-63000 CLERMONT-FERRAND

\*Corresponding author: Dr Isabelle Papet, Unité de Nutrition Humaine, INRA Theix, 63122 Saint-Genès-Champanelle, France. Telephone: +33 4 73 62 42 01. Fax: +33 4 73 62 47 55. E-mail: Isabelle.Papet@clermont.inra.fr.

#### 1 Abstract

- 2 Purpose Healthy ageing is associated with higher levels of glutathione. The study aimed to determine whether
- 3 long-term dietary fortification with cysteine increases cysteine and glutathione pools thus, alleviating age-
- 4 associated low-grade inflammation and resulting in global physiological benefits.
- 5 *Methods* The effect of a 14-wk dietary fortification with cysteine was studied in non-inflamed (NI, healthy at
- 6 baseline) and in spontaneously age-related low-grade inflamed (LGI, prefrail at baseline) 21-mo-old rats. 57 NI
- 7 rats and 14 LGI rats received cysteine-supplemented diet (4.0 g/kg of free cysteine added to the standard diet
- 8 containing 2.8 g/kg cysteine). 56 NI rats and 16 LGI rats received a control alanine-supplemented diet.
- 9 *Results* Cysteine fortification in NI rats increased free cysteine (P < 0.0001) and glutathione (P < 0.03) in the
- 10 liver and the small intestine. In LGI rats, cysteine fortification increased total non-protein cysteine (P < 0.0007)
- 11 and free cysteine (P < 0.03) in plasma, and free cysteine (P < 0.02) and glutathione (P < 0.01) in liver. Food
- 12 intake decreased over time in alanine-fed rats ( $r^2 = 0.73$ , P = 0.0002), whereas it was constant in cysteine-fed rats
- 13  $(r^2 = 0.02, P = 0.68)$ . Cysteine fortification did not affect inflammatory markers, mortality, body weight loss, or
- 14 tissue masses.

15 Conclusion Doubling the dietary intake of cysteine in old rats increased cysteine and glutathione pools in

16 selected tissues. Additionally, it alleviated the age-related decline in food intake. Further validation of these

- 17 effects in the elderly population suffering from age-related anorexia would suggest a useful therapeutic approach
- 18 to the problem.
- 19

21

20 Key words Ageing rats . Dietary cysteine . Frailty . Low-grade inflammation

#### 22 Abbreviations

23	LBP	lipopolysaccharide binding protein			
24	LGI	low-grade inflamed			
25	NAC	N-acetyl cysteine			
26	NI	non-inflamed			
27	sTNFR-1	soluble tumor necrosis factor-alpha receptor-1			
28					

29 Introduction

30

31 As the number of older individuals around the world is increasing dramatically, defining optimal nutrition for 32 healthy ageing, i.e. a delay in the development of chronic disease [1], is an important challenge. Ageing per se 33 and/or age-related diseases are associated with a progressive rise in oxidative stress [2], which plays a role in the 34 expansion of homeosteny, notably low-grade inflammation and sarcopenia [3]. The main intra-cellular anti-35 oxidant is glutathione and imbalances in glutathione levels per se are thought to play a role in the ageing process 36 [4]. Intra-cellular glutathione concentration decreases with age in various tissues in ageing rats [5]. Along the 37 same lines, higher levels of glutathione are associated with better physical and mental health in elderly [6, 7]. 38 Thus, dietary treatment aiming at increasing anti-oxidant pools, such as glutathione levels, could promote a 39 healthy ageing.

40 Glutathione is a tripeptide composed of glutamic acid, cysteine and glycine. Intra-cellular glutathione 41 levels are regulated by a complex series of mechanisms and cysteine is the rate limiting substrate for glutathione 42 synthesis [8]. Cysteine is obtained from dietary proteins, breakdown of body proteins and glutathione. It can also 43 be endogenously synthesised from methionine and serine through the transsulfuration pathway. When the 44 endogenous disposal of cysteine is insufficient regarding its metabolic utilizations, it becomes an indispensable 45 amino acid [9]. Indeed, increasing cysteine content of the diet of septic rats allows restoration of the liver 46 glutathione pool [10] and limits body weight loss and muscle wasting [11]. In spite of the fact that interventional 47 studies with the pharmacological molecule N-acetyl-cysteine (NAC) exhibited potential beneficial targeted 48 effects for elderly [12-15], health-promoting effects of long-term dietary fortification with cysteine itself remain 49 unevaluated.

The primary objective of the study was to determine whether long-term cysteine fortification would increase cysteine and glutathione levels in healthy (*i.e.* non-inflamed) old rats and consequently prevent ageassociated development of inflammation and other adverse outcomes (*i.e.* towards a prefrail/frail status). The secondary objective was to investigate whether cysteine fortification is able to improve the prefrail status in elderly rats with low-grade inflammation. Biochemical targets were cysteine, glutathione, and inflammatory markers; physiological outcomes were mortality, food intake, and body, tissue and organ weights.

- 58

57

59

Comment citer ce document : Vidal, K., Breuille, D., Serrant, P., Denis, P., Glomot, F., Bechereau, F., Papet, I. (2014). Long-term cysteine fortification impacts cysteine/glutathione homeostasis and food intake in ageing rats. European Journal of Nutrition, 53 (3), 963 - 971., DOI : 10.1007/s00394-013-0600-0 61

62 Animals

63

71

73

The experiments were conducted in accordance with the French National Research Council's Guidelines for the Care and Use of Laboratory Animals. Wistar male rats were bred in our conventional (non-specific-pathogenfree) animal facility (Unité Expérimentale de Nutrition Comparée, INRA, Theix, France). They were maintained in collective cages (3 to 4 per cage) under controlled conditions (temperature 21°C, relative humidity 55%, 12-h dark period starting at 20:00) with free access to water and standard diet until the experiment. The standard diet (A04 pellets from Scientific Animal Food and Engineering (SAFE), Villemoisson-sur-Orge, France) was composed of 16% protein, 3% fat, 60% carbohydrate, 12% water, fibers, vitamins, and minerals.

72 Experimental design

The effect of a 14-wk dietary fortification with cysteine was studied in non-inflamed and low-grade inflamed 21 mo old rats (Fig. 1).

The pre-experimental period, plasma concentrations of fibrinogen and  $\alpha_2$ -macroglobulin were measured at the ages of 18, 19 and 20.5 mo. Rats were weighed at the beginning and at the end of the preexperimental period. Apparently ill rats and/or rats that exhibited pathological values of acute phase proteins (i.e. values predictive of short-term mortality according to our previous observations [16]), were excluded.

80 At the age of 21 mo rats were distributed into 2 sets based on hierarchical clustering using Ward 81 distance on the following variables:  $\alpha_2$ -macroglobulin, fibrinogen, body weight and body weight change during 82 the pre-experimental period (XLSTAT, version 7.5 software (Addinsoft, Paris, France)). A posteriori, non-83 inflamed (NI, i.e. healthy at baseline) rats were distinguished from low-grade inflamed (LGI, i.e. prefrail at 84 baseline) rats using an  $\alpha_2$ -macroglobulin plasma threshold of 82 mg/L, which corresponds to the mean plasma 85 level + 2 SD from adult rats [16]. At baseline, LGI rats did not exhibit any apparent pathologies or pathological 86 levels of  $\alpha_2$ -macroglobulin. They were considered as prefrail because their health status was expected to 87 deteriorate more with ageing than the NI rats. Group names (numbers of rats) were as follows: NI-Ala (n = 56) 88 and NI-Cys (n = 57) for NI rats receiving alanine-supplemented (Ala) and cysteine-supplemented (Cys) diets, 89 respectively; and LGI-Ala (n = 16) and LGI-Cys (n = 14) for LGI rats receiving Ala and Cys diets, respectively. 90 Cys and Ala diets were prepared by supplementation of the standard diet A04 with amino acids and distributed 91 as pellets. Cys diet contained 6.8 g/kg diet i.e. 2.8 g/kg from dietary proteins plus 4 g/kg as free L-cysteine 92 (Sigma). Cysteine level has been chosen taking into account the efficient level (11 g/kg diet) in septic rats [11] 93 and the fact that age-associated inflammation is much lower than in sepsis. The selected cysteine level was in the 94 same range as NAC treatment performed in rats [17]. Ala diet contained 2.8 g/kg diet of cysteine from dietary 95 proteins and 2.9 g/kg diet of free L-alanine (Jerafrance) to make it iso-nitrogenous to Cys diet. Rats were 96 maintained in collective cages (2 to 3 per cage) and received the experimental diets ad libitum for 14 wk. Food 97 intake was recorded weekly per cage, and individual daily food intake was calculated according to the number of 98 rats per cage. When a death or a moribund condition occurred in a cage, the corresponding data was eliminated. 99 Blood was sampled from the lateral tail vein following 2, 6, and 13 wk of supplementation. Plasma was isolated 100 and aliquots were stored at -80°C. After 14 wk of supplementation (24 month of age), rats were killed under

Comment citer ce document :

101 general anaesthesia induced by intra-peritoneal injection of pentobarbital (6 mg/100 g body weight, 0.1 mL/100 102 g body weight, Sanofi, Libourne, France) by exsanguinations through the abdominal aorta. Aliquots of plasma 103 were collected and stored at -80°C. Posterior leg skeletal muscles, liver, small intestine, colon, and kidneys were 104 rapidly isolated. Small intestine and colon were flushed with ice-cold NaCl (9 g/L). The isolated tissues and 105 organs were blotted dry and weighed. Liver and small intestine were frozen in liquid nitrogen and stored at -106 80°C until cysteine and glutathione analyses. 107 108 109 **Biochemical analyses** 110 111 Plasma acute phase proteins, such as  $\alpha_2$ -macroglobulin (CV 18%), fibrinogen (CV 2%), albumin (CV 15%) and 112 LPS-binding protein (LBP, lower detection: 1.56 ng/ml) and serum soluble tumor necrosis factor-alpha receptor-113 1 (sTNFR-1, lower detection: 15.6 pg/ml, CV 5%) were measured as previously described [16]. Total 114 glutathione (reduced plus oxidized) was quantified with a spectrophotometer using a standard enzymatic 115 recycling procedure and 5,5'-dithio-bis-2-nitrobenzoic acid as oxidant (CV 1%) [18]. Total non-protein cysteine 116 (cysteine plus cystine and cysteine bound to proteins through disulfide bridges) was measured with a colorimeter 117 in plasma or tissue homogenates treated with dithiothreitol before deproteinization (CV 8%) [19, 20]. Free 118 cysteine (cysteine plus cystine) was quantified with the same method but dithiothreitol treatment was performed 119 after protein precipitation. The difference between total non-protein cysteine and free cysteine provided the 120 protein bound cysteine (cys-prot) value. 121

#### 122 Statistical analysis

124 Survival curves were generated up to 13 wk of dietary treatment by the Kaplan-Meyer method and compared by 125 log-rank test. Other data are given as means  $\pm$  SEM. Linear regression was used to assess the relationship 126 between mean food intake and time. Since rats were housed in collective cages and NI and LGI subgroups were 127 made a posteriori, for this analysis NI and LGI subgroups were combined. The Mann-Whitney U test was used 128 to analyze effects of cysteine fortification: i) NI-Cys plus LGI-Cys vs NI-Ala plus LGI-Ala, ii) NI-Cys vs NI-Ala 129 and iii) LGI-Cys vs LGI-Ala. Differences between NI-Ala and LGI-Ala, and between NI-Cys and LGI-Cys were 130 also analyzed for studying the effect of basal low-grade inflammation using the Mann-Whitney U test. The 131 Wilcoxon's signed rank test was used to compare paired-data obtained at different time-points within a group. 132 These non-parametric tests were used since variances were not homogenous for most of the variables. P values  $\leq$ 133 0.05 were considered significant. Statistical analyses were performed using StatView for Windows, version 5 134 software (SAS Institute, Cary, NC). 135

136 Results

138 Pre-experimental characteristics of the aged rats

139

137

140 Baseline plasma concentrations of  $\alpha_2$ -macroglobulin and fibrinogen, body weight and body weight change from

141 NI-Cys and LGI-Cys rats were not significantly different from those of respective Ala groups (Table 1).

123

142 According to the experimental design, baseline concentrations of  $\alpha_2$ -macroglobulin were significantly higher in 143 LGI rats than in NI rats, being 471 % higher in LGI-Ala rats and 436 % higher in LGI-Cys rats than in the 144 corresponding NI groups. In the same way, baseline concentrations in fibrinogen were 27 % higher in LGI-Ala 145 rats and 39 % higher in LGI-Cys rats than in the corresponding NI groups. Body weight and body weight change 146 during the pre-experimental period were not significantly different between LGI-Ala and LGI-Cys groups. LGI-147 Ala rats were lighter than NI-Ala rats, reflecting that LGI-Ala had lost body weight during the pre-experimental

148 149

period.

150 Mortality during dietary treatments

151

152 During the experimental period, mortality rate was 12, 9, 31 and 43 % in NI-Ala, NI-Cys, LGI-Ala and LGI-Cys 153 groups, respectively. As expected, comparison of the survival curves generated by Kaplan-Meyer method (not 154 shown) indicated that mortality was higher in LGI-Ala and LGI-Cys rats (prefrail at baseline) than in the 155 corresponding NI groups (healthy at baseline) (Logrank test = 2.79, P = 0.095 and Logrank test = 4.95, P =156 0.026, respectively). Mortality was not significantly different between NI-Ala and NI-Cys rats (Logrank test = 157 0.134, P = 0.71), neither between LGI-Cys and LGI-Ala rats (Logrank test = 0.035, P = 0.85). All the results 158 described below were obtained from survivors (i.e. NI-Ala, n = 49, NI-Cys, n = 52, LGI-Ala, n = 11 and LGI-159 Cys, n = 8).

161 Food intake, body weight, and organ weights

162

160

163 Food intake of rats fed with Ala diet (NI-Ala plus LGI-Ala rats) decreased over time (P = 0.0002), whereas it 164 was constant in rats fed with Cys diet (NI-Cys plus LGI-Cys) (Fig. 2). From wk 6 to wk 13 the food intake was 3

165 to 16 % higher in Cys-fed rats than in Ala-fed rats (P < 0.0001 to 0.03).

166 Final body weight was not significantly different between NI-Ala and NI-Cys rats (P = 0.22), neither 167 between LGI-Ala and LGI-Cys rats (P = 0.87) (Table 2). Final body weight of LGI-Ala and LGI-Cys rats 168 (prefrail at baseline) was respectively 11 and 15 % lower than in the corresponding NI groups (healthy at 169 baseline).

170 Absolute and relative weights of liver were respectively 10 and 8 % higher in NI-Cys rats than in NI-171 Ala rats, but were not significantly different between LGI-Ala and LGI-Cys rats (Table 2). Liver relative weight 172 in LGI-Ala and LGI-Cys rats was respectively 23 and 20 % higher in than in corresponding NI groups. Absolute 173 and relative weights of small intestine and colon were not significantly different between NI-Ala and NI-Cys 174 rats, neither between LGI-Ala and LGI-Cys rats. Relative weight of small intestine, and absolute and relative 175 weight of colon were respectively 30, 12, and 27 % higher in LGI-Ala rats than in NI-Ala rats.

176 Cysteine fortification had no significant effect on kidney or skeletal muscle weights whatever the basal 177 inflammatory status of the rats (not shown). Kidney weight in LGI-Ala and LGI-Cys rats was respectively 34 178 and 26 % higher than in the corresponding NI groups. Differences between LGI groups and the corresponding 179 NI groups were not significant for all studied skeletal muscles, excepted for EDL which was 10 % lighter in 180 LGI-Cys rats than in NI-Cys rats (P = 0.043).

181

#### 182 Cysteine concentrations in plasma and splanchnic tissues

183

184 Plasma total non-protein cysteine concentration was not significantly different between NI-Ala and NI-Cys rats 185 (P = 0.47), but was 40 % higher in LGI-Cys rats than in LGI-Ala rats (Fig. 3A). This variation reveals a 186 corrective effect of dietary cysteine supplementation in rats being prefrail at baseline, since plasma total non-187 protein cysteine concentration was 21% lower in LGI-Ala rats than in NI-Ala rats. Plasma free cysteine (i.e. 188 cysteine plus cystine) concentration in LGI-Cys rats was 50 % higher than in LGI-Ala rats and 23 % higher than 189 in NI-Cys rats. Cysteine fortification did not significantly modify the amount of cysteine bound to plasma 190 proteins through disulfide bridges (cys-prot). Nevertheless, this parameter was 34 % lower in LGI-Ala rats than 191 in NI-Ala rats. 192 Total non-protein cysteine and cys-prot concentrations in liver and small intestine were not significantly 193 affected by cysteine fortification, neither by the basal inflammatory status (Fig. 4A and 5A). In the liver, free 194 cysteine concentration was significantly higher in the Cys-supplemented rats than in the Ala rats: 16 and 44 % 195 higher in NI-Cys and LGI-Cys rats than in the corresponding Ala groups. In addition, free cysteine concentration 196 in the liver was 16 % lower in LGI-Ala rats than in NI-Ala rats. In the small intestine, free cysteine concentration 197 was 24 % higher in NI-Cys rats than in NI-Ala rats.

198

199 Splanchnic tissues glutathione concentrations and liver  $\gamma$ -glutamylcysteine synthetase activity

200

201 Liver glutathione concentration was significantly higher in Cys-supplemented rats than in the Ala rats: 15 and 202 20 % higher in NI-Cys and LGI-Cys rats than in the corresponding Ala groups. It was lower in rats being prefrail 203 at baseline than in rats being healthy at baseline: 12 and 8 % lower in LGI-Ala and LGI-Cys rats than in the 204 corresponding NI groups (Fig. 4B). Liver  $\gamma$ -glutamylcysteine synthetase activity was significantly lower in Cys-205 supplemented rats that in the Ala rats: 32 and 68 % lower in NI-Cys and LGI-Cys rats than in the corresponding 206 Ala groups (Fig. 4C). This enzyme activity was 45 % higher in LGI-Ala rats than in NI-Ala rats.

207 Small intestine glutathione concentration was 3 % higher in NI-Cys rats than in NI-Ala rats and 5 % 208 higher in LGI-Ala rats than in NI-Ala rats (Fig. 5).

210 Acute phase proteins and sTNFR-1 responses to cysteine fortification

211

209

212 At any time points of the kinetic (wk -2, wk 2, wk 6 and wk 13), plasma  $\alpha_2$ -macroglobulin and fibrinogen 213 concentrations were not significantly different between NI-Ala and NI-Cys rats and neither between LGI-Ala 214 and LGI-Cys rats (P = 0.09 to 0.94) (Fig. 6). As expected,  $\alpha_2$ -macroglobulin and fibrinogen were significantly 215 higher in LGI-Ala and LGI-Cys rats (prefrail at baseline) than in the corresponding NI groups (healthy at 216 baseline). Time-dependent increases in  $\alpha_2$ -macroglobulin and fibrinogen concentrations were observed in all 217 groups: i) final  $\alpha_2$ -macroglobulin concentration was significantly higher than its basal value by 582, 670, 488 218 and 680 % in NI-Ala, NI-Cys, LGI-Ala and LGI-Cys rats, respectively, and ii) final fibrinogen concentration 219 was significantly higher than its basal value by 36, 53, 48 and 32 % in NI-Ala, NI-Cys, LGI-Ala and LGI-Cys 220 rats, respectively. 221 Plasma LBP and sTNFR-1 concentrations were quantified at wk -2, wk 6 and wk 13 (data not shown).

222 At any time points, no significant difference in levels of LBP or sTNFR-I were observed between NI-Ala and 223 NI-Cys rats and neither between LGI-Ala and LGI-Cys rats (P = 0.07 to 0.80). Time-dependent increases in LBP and sTNFR-1 concentrations were observed in all groups: i) final LBP concentration was higher than its basal
value by 114, 59, 222 and 167 % in NI-Ala, NI-Cys, LGI-Ala and LGI-Cys rats, respectively, ii) final sTNFR-1
concentration was higher than its basal value by 102, 79, 153, and 191 % in NI-Ala, NI-Cys, LGI-Ala and LGICys rats, respectively.

228 Concentration of plasma albumin quantified at euthanasia was not significantly different between NI-229 Ala and NI-Cys rats and neither between LGI-Ala and LGI-Cys rats (data not shown). As expected, it was lower 230 in rats being prefrail at baseline than in rats being healthy at baseline: 31 and 30 % lower in LGI-Ala and LGI-231 Cys rats than in respective NI groups. A strong correlation was observed between plasma albumin and plasma 232 cys-prot concentrations ( $r^2 = 0.277$ , P < 0.0001).

### 234 Discussion

233

235

To our knowledge, this is the first study to determine whether long-term (14 wk) cysteine fortification (6.8 vs.
2.8 g/kg) can exert beneficial effects in NI (*i.e.* healthy at baseline) and LGI (*i.e.* prefrail at baseline) old rats.
This is also the first study reporting that cysteine supplementation in the diet increased the spontaneous food intake of old rats.

240 In NI (i.e. healthy at baseline) rats, cysteine fortification was efficient to increase free cysteine and 241 glutathione pools in liver and small intestine. In agreement with the idea that ageing is a cysteine deficient 242 syndrome [21], these increases could result from a correction of age-induced decrease in cysteine and 243 glutathione pools. One cannot rule out an accumulation above normal ranges. However, such an accumulation is 244 rather unlikely for cysteine due to the strong regulation of free cysteine pool by oxidation and degradation, 245 mainly by cysteine dioxygenase [22]. The increase of glutathione pool in liver is consistent with the fact that 246 NAC supplementation (3 g/kg diet) was efficient to reverse the age-associated decrease in liver glutathione in 247 old rats [17]. Similarly, in a elderly cohort, supplementation with NAC and glycine for 3 wk restored the 248 concentration and the rate of synthesis of blood glutathione [15]. In the present study, the observed increase in 249 liver glutathione pool could directly result from an increase in free cysteine since availability of cysteine is a rate 250 limiting factor for glutathione synthesis [23]. The finding of reduced  $\gamma$ -glutamylcysteine synthetase activity with 251 cysteine fortification further ruled out the possibility of an increase in its activity as the underlying cause for 252 increased glutathione levels. The most logical explanation for this reduction in enzyme activity is the feedback 253 inhibition exerted by glutathione itself [4]. In a previous study, heat treatment plus NAC also resulted in a 254 similar inhibition of  $\gamma$ -glutamylcysteine synthetase activity [24]. Following increased glutathione concentration 255 in the liver, a subsequent increase in the hepatic efflux rate and a more favourable uptake of glutathione by extra-256 hepatic tissues are expected. This would result in better protection against pathological oxidative challenges in 257 aged rats, but this remains untested. Regardless of the mechanism, cysteine fortification-induced increases in free 258 cysteine and glutathione pools in liver and small intestine did not affect the kinetics of inflammatory markers in 259 rats that were healthy at baseline. This is in contrast to the reported effects of NAC in other models [12, 25, 26]. 260 Further, cysteine fortification-induced effects on cysteine and glutathione pools did not affect final organ, muscle 261 or body weights (except increase in liver weight), or mortality rate in rats that were healthy at baseline. This lack 262 of an effect on body weight rejects the potential relationship between dietary cysteine and obesity [27]. The 263 absence of exercise in the experimental protocol may explain the lack of effect on the skeletal muscle weight. 264 Indeed, NAC supplementation plus physical activity have been reported to improve muscular performance,

265 especially in frail elderly subjects with poor plasma arginine levels [12]. Altogether, the present results support 266 that a deficiency in cysteine or glutathione is not a key player in the age-associated development of inflammation 267 in rats that are healthy at baseline. It rather reflects the development of a subclinical pathology as attested by the 268 increased levels of inflammatory markers reached at the end of the experiment. It has already been stressed that 269 the distinction between ageing *per se* and age-associated pathology is almost impossible [28].

270 In LGI (*i.e.* prefrail at baseline) rats, the major effects of cysteine fortification were similar to those 271 observed in NI rats that were healthy at baseline *i.e.* an increase in plasma free and total non-protein cysteine 272 pools, an increase in free cysteine and glutathione pools along with a decrease in the activity of  $\gamma$ -273 glutamylcysteine synthetase in the liver. These effects of cysteine fortification are considered beneficial since 274 most of these parameters were altered in low-grade inflamed rats compared to healthy ones (*i.e.* in LGI-Ala vs. 275 NI-Ala groups). Nevertheless, cysteine fortification did not alleviate the progression of inflammation in rats that 276 showed low-grade inflammation at baseline. The mortality rate of LGI rats was higher than that for NI rats, and 277 LGI survivors exhibited a lower body weight, higher intestine and kidneys weights than the NI survivors. At the 278 end of the experiment, the inflammatory markers of LGI rats reached pathological levels [16]. These 279 observations confirm that basal low-grade inflammation is a predictive factor of frailty and increased mortality 280 [16, 29-31]. Altogether, cysteine fortification did not stop the progression from prefrailty to frailty and the basal 281 low-grade inflammation seems to be a likely consequence of nascent pathologies.

282 The most unexpected result of our experiment was that cysteine fortification alleviated the age-283 associated decrease in food intake. Our data clearly show that the progressive age-related decrease of food intake 284 observed in ageing rats was suppressed when the animals were supplemented with cysteine. This beneficial 285 effect could be of great importance since decreased food intake has been reported as a robust factor in predicting 286 mortality in hospitalized patients, being even superior to weight loss [32]. While further validation of this effect 287 would be prudent, published data does indeed, support such an effect. In a model of LPS-induced anorexia in 288 mice, it has been shown that food intake is higher when brain glutathione is higher [33]. Brain anti-oxidative 289 defences, notably glutathione, are known to decrease with age [34]. It is possible that the increased availability 290 of cysteine in old rats receiving cysteine fortification allowed a better transport of cysteine into the brain and/or a 291 higher synthesis of glutathione in this organ. Indeed, the transport of cysteine into the brain has been shown to be 292 an important determinant of brain glutathione [35]. In addition, NAC supplementation led to an enhancement of 293 glutathione concentration in brain [14]. These data suggest that the maintenance of food intake in our Cys-294 supplemented rats is due to by an increase in brain glutathione. Unfortunately, this hypothesis cannot be 295 confirmed since no brain sampling was performed in the present study. Other mechanisms cannot be ruled out, 296 notably those related to pro-inflammatory cytokines playing a role in anorexia [36]. Such cytokines have been 297 shown to be decreased in brain of aged rats receiving NAC along with  $\alpha$ -tocopherol and  $\alpha$ -lipoic acid [37].

298 In conclusion, long-term cysteine fortification, leading to the doubling of its dietary supply, appears to 299 be safe (mortality and organ weights unchanged) and efficient in increasing the size of cysteine and glutathione 300 pools in rats that were either healthy or prefrail at baseline. Unfortunately, it did not counteract the development 301 of inflammation in rats that were non-inflamed at baseline nor did it stop the progression of inflammation in rats 302 that showed low-grade inflammation at baseline. Age-associated inflammation seems to be rather a marker of 303 subclinical and clinical pathology than a consequence of a possible cysteine/glutathione deficiency. The novel 304 finding of the study, which needs to be confirmed, was that cysteine fortification inhibited the age-associated 305 anorexia.

306 307 Acknowledgments The authors would like to acknowledge Marie Perrot for help in the statistical analysis, 308 Jacques Vuichoud for determination of amino acids in the standard diet, the Staff of the Unité Expérimentale de 309 Nutrition Comparée for animal care, and Viral Vishnuprasad Brahmbhatt (Nestlé Research Center) for 310 improving the manuscript. This work was supported by Institut National de la Recherche Agronomique (INRA), 311 France and Nestlé, Switzerland. 312 313 Conflict of interest K. Vidal, D. Breuillé and P. Serrant are employees of Nestec Ltd. K. Vidal, D. Breuillé, and 314 I. Papet are co-inventors on a patent related to the present study. P. Denis, F. Glomot and F. Béchereau, no 315 conflict of interest.

316

317	Referen	nces
318		
319	1.	Fries JF (1983) The compression of morbidity. Milbank Memorial Fund Quarterly-Health and Society
320		61:397-419
321	2.	Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78:547-581
322	3.	Meng SJ, Yu LJ (2010) Oxidative Stress, Molecular Inflammation and Sarcopenia. Int J Mol Sci
323		11:1509-1526
324	4.	Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009) Glutathione dysregulation
325		and the etiology and progression of human diseases. Biol Chem 390:191-214
326	5.	Mosoni L, Breuillé D, Buffière C, Obled C, Patureau Mirand P (2004) Age-related changes in
327		glutathione availability and skeletal muscle carbonyl content in healthy rats. Exp Gerontol 39:203-210
328	6.	Lang CA, Naryshkin S, Schneider DL, Mills BJ, Lindeman RD (1992) Low blood glutathione levels in
329		healthy aging adults. J Lab Clin Med 120:720-725
330	7.	Julius M, Lang CA, Gleiberman L, Harburg E, DiFranceisco W, Schork A (1994) Glutathione and
331		morbidity in a community-based sample of elderly. J Clin Epidemiol 47:1021-1026
332	8.	Maher P (2005) The effects of stress and aging on glutathione metabolism. Ageing Res Rev 4:288-314
333	9.	Obled C, Papet I, Breuillé D (2004) Sulfur-containing amino acids and glutathione in diseases. In:
334		Cynober LA (ed) Metabolic and Therapeutic Aspects of Amino Acids in Clinical Nutrition. CRC Press,
335		p 667-687
336	10.	Obled C, Papet I, Breuille D (2002) Metabolic bases of amino acid requirements in acute diseases.
337		Current Opinion in Clinical Nutrition and Metabolic Care 5:189-197
338	11.	Breuillé D, Béchereau F, Buffière C, Denis P, Pouyet C, Obled C (2006) Beneficial effect of amino acid
339		supplementation, especially cysteine, on body nitrogen economy in septic rats. Clin Nutr 25:634-642
340	12.	Hauer K, Hildebrandt W, Sehl Y, Edler L, Oster P, Dröge W (2003) Improvement in muscular
341		performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J Mol
342		Med 81:118-125
343	13.	Arranz L, Fernández C, Rodríguez A, Ribera JM, De la Fuente M (2008) The glutathione precursor N-
344		acetylcysteine improves immune function in postmenopausal women. Free Radical Biol Med 45:1252-
345		1262
346	14.	Kanwar SS, Nehru B (2007) Modulatory effects of N-acetylcysteine on cerebral cortex and cerebellum
347		regions of ageing rat brain. Nutr Hosp 22:95-100
348	15.	Sekhar RV, Patel SG, Guthikonda AP, Reid M, Balasubramanyam A, Taffet GE, Jahoor F (2011)
349		Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary
350		cysteine and glycine supplementation. Am J Clin Nutr 94:847-853
351	16.	Mayot G, Vidal K, Martin JF, Breuillé D, Blum S, Obled C, Papet I (2007) Prognostic values of alpha2-
352		macroglobulin, fibrinogen and albumin in regards to mortality and frailty in old rats. Exp Gerontol
353		42:498-505
354	17.	Grattagliano I, Portincasa P, Cocco T, Moschetta A, Di Paola M, Palmieri VO, Palasciano G (2004)
355		Effect of dietary restriction and N-acetylcysteine supplementation on intestinal mucosa and liver
356		mitochondrial redox status and function in aged rats. Exp Gerontol 39:1323-1332

Comment citer ce document : Vidal, K., Breuille, D., Serrant, P., Denis, P., Glomot, F., Bechereau, F., Papet, I. (2014). Long-term cysteine fortification impacts cysteine/glutathione homeostasis and food intake in ageing rats. European Journal of Nutrition, 53 (3), 963 - 971., DOI : 10.1007/s00394-013-0600-0

357	18.	Malmezat T, Breuillé D, Pouyet C, Patureau Mirand P, Obled C (1998) Metabolism of cysteine is
358		modified during the acute phase of sepsis in rats. J Nutr 128:97-105
359	19.	Gaitonde MK (1967) A spectrophotometric method for the direct determination of cysteine in the
360		presence of other naturally occurring amino acids. Biochem J 104:627-633.
361	20.	Malloy MH, Rassin DK, Gaull GE (1981) A method for measurement of free and bound plasma
362		cyst(e)ine. Anal Biochem 113:407-415
363	21.	Dröge W (2005) Oxidative stress and ageing: is ageing a cysteine deficiency syndrome? Phil Trans R
364		Soc B 360:2355-2372
365	22.	Stipanuk MH, Ueki I, Dominy JE, Simmons CR, Hirschberger LL (2009) Cysteine dioxygenase: a
366		robust system for regulation of cellular cysteine levels. Amino Acids 37:55-63
367	23.	Griffith OW (1999) Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free
368		Radical Biol Med 27:922-935
369	24.	Morrison JP, Coleman MC, Aunan ES, Walsh SA, Spitz DR, Kregel KC (2005) Thiol supplementation
370		in aged animals alters antioxidant enzyme activity after heat stress. J Appl Physiol 99:2271-2277
371	25.	Hack V, Breitkreutz R, Kinscherf R, Röhrer H, Bärtsch P, Taut F, Benner A, Dröge W (1998) The
372		redox state as a correlate of senescence and wasting and as a target for therapeutic intervention. Blood
373		92:59-67
374	26.	Kim CJ, Kovacs-Nolan J, Yang C, Archbold T, Fan MZ, Mine Y (2009) L-cysteine supplementation
375		attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim
376		Biophys Acta 1790:1161-1169
377	27.	Elshorbagy AK, Smith AD, Kozich V, Refsum H (2012) Cysteine and obesity. Obesity 20:473-481
378	28.	Ferrucci L (2008) The Baltimore Longitudinal Study of Aging (BLSA): A 50-Year-Long Journey and
379		Plans for the Future. Journals of Gerontology Series a-Biological Sciences and Medical Sciences
380		63:1416-1419
381	29.	Cohen HJ, Harris T, Pieper CF (2003) Coagulation and activation of inflammatory pathways in the
382		development of functional decline and mortality in the elderly. Am J Med 114:180-187
383	30.	Ferrucci L, Penninx BWJH, Volpato S, Harris TB, Bandeen-Roche K, Balfour J, Leveille SG, Fried LP,
384		Guralnick JM (2002) Change in muscle strength explains accelerated decline of physical function in
385		older women with high interleukin-6 serum levels. J Am Geriatr Soc 50:1947-1954
386	31.	Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WHJ, Heimovitz H, Cohen HJ,
387		Wallace R (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in
388		the elderly. Am J Med 106:506-512
389	32.	Landi F, Laviano A, Cruz-Jentoft AJ (2010) The Anorexia of Aging: Is It a Geriatric Syndrome? J Am
390		Med Dir Assoc 11:153-156
391	33.	Hernadfalvi N, Langhans W, von Meyenburg C, Onteniente B, Richard D, Arsenijevic D ( 2007) Role
392		for glutathione in the hyposensitivity of LPS-pretreated mice to LPS anorexia. Eur Cytokine Netw
393		18:86-92
394	34.	Chen TS, Richie JP, Jr., Lang CA (1989) The effect of aging on glutathione and cysteine levels in
395		different regions of the mouse brain. Proc Soc Exp Biol Med 190:399-402

396	35.	Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, Swanson RA (2006) Neuronal glutathione
397		deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci 9:119-
398		126
399	36.	Gautron L, Layé S (2009) Neurobiology of Inflammation-Associated Anorexia. Frontiers in
400		Neuroscience 3:59
401	37.	Thakurta IG, Chattopadhyay M, Ghosh A, Chakrabarti S (2012) Dietary supplementation with N-acetyl
402		cysteine, $\alpha$ -tocopherol and $\alpha$ -lipoic acid reduces the extent of oxidative stress and proinflammatory state
403		in aged rat brain. Biogerontology 13:479-488
404		
405		

400	Figure captions
407	
408	Fig.1. Experimental design.
409	
410	Fig. 2. Effect of cysteine fortification on food intake in ageing rats.
411	Ala: combined NI-Ala plus LGI-Ala groups, Cys: combined NI-Cys plus LGI-Cys groups.
412	
413	Fig. 3. Effect of cysteine fortification on plasma non-protein cysteine concentration in old rats being non
414	inflamed or low-grade inflamed at baseline.
415	Bars are means ± SEM. Panel A, upper SEM stand for total cysteine, lower SEM for free cysteine or protein
416	linked cysteine. Symbols on the bars illustrate significant difference for free cysteine or protein-linked cysteine
417	symbols above the bars for total (free plus protein-linked) cysteine. *, ** different from corresponding NI group
418	P < 0.04 and $P < 0.0007$ , respectively. † different from corresponding Ala group $P < 0.006$ .
419	
420	Fig. 4. Effect of cysteine fortification on liver non-protein cysteine and glutathione concentrations and on $\gamma$
421	glutamylcysteine synthetase (γ-GCS) activity in old rats being non-inflamed or low-grade inflamed at baseline.
422	Bars are means ± SEM. Panel A, upper SEM stand for total cysteine, lower SEM for free cysteine or protein
423	linked cysteine. Symbols on the bars illustrate significant difference for free cysteine. * different from
424	corresponding NI group $P < 0.05$ . †, †† different from corresponding Ala group $P < 0.02$ and $P < 0.0004$
425	respectively.
426	
427	Fig. 5. Effect of cysteine fortification on small intestine non-protein cysteine and glutathione concentrations in
428	old rats being non-inflamed or low-grade inflamed at baseline.
429	Bars are means ± SEM. Panel A, upper SEM stand for total cysteine, lower SEM for free cysteine or protein
430	linked cysteine. Symbols on the bars illustrate significant difference for free cysteine. * different from
431	corresponding NI group $P < 0.04$ . †, †† different from corresponding Ala group $P < 0.03$ and $P < 0.0001$
432	respectively.
433	
434	Fig. 6. Effect of cysteine fortification on plasma acute phase protein kinetics in ageing rats being non-inflamed
435	or low-grade inflamed at baseline.
436	Bars are means $\pm$ SEM. <sup>a, b, c, d</sup> labelled bars within a group without a common letter differ, $P < 0.05$ . * differen
	from the same time point of the corresponding NL group $P < 0.03$

Table 1. Plasma acute phase protein concentrations, body weight and body weight change before dietary supplementation<sup>\$</sup>

Group	NI-Ala	NI-Cys	LGI-Ala	LGI-Cys
	( <i>n</i> = 56)	( <i>n</i> = 57)	( <i>n</i> = 16)	( <i>n</i> = 14)
$\alpha_2$ -macroglobulin at wk -2, <i>mg/L</i>	$35 \pm 3$	$33 \pm 2$	202 ± 22***	177 ± 25***
Fibrinogen at wk -2, g/L	$3.07\pm0.10$	$2.90\pm0.08$	3.91 ± 0.20**	$4.04 \pm 0.18^{**}$
Body weight at wk 0, g	$664 \pm 11$	$659\pm9$	$612 \pm 13*$	$646\pm25$
Pre-experimental body weight change, %/13 wk	$0.15\pm0.80$	$1.54\pm0.57$	$-2.53 \pm 0.93*$	$-0.74 \pm 1.39$

<sup>-</sup><sup>s</sup> Data are means  $\pm$  SEM. \*, \*\*, \*\*\* different from corresponding NI group *P* < 0.02, *P* < 0.001, *P* < 0.0001, respectively

Table 2. Effects of cysteine fortification on body and organ weights in old rats being non-inflamed or low-grade inflamed at baseline<sup>\$</sup>

Group	NI-Ala NI-Cys		LGI-Ala	LGI-Cys	
	( <i>n</i> = 49)	( <i>n</i> = 52)	( <i>n</i> = 11)	( <i>n</i> = 8)	
Final body weight (BW), g	$609 \pm 15$	627 ± 11	$539 \pm 19$ **	$533 \pm 46*$	
Liver, <i>g</i>	$18.1\pm0.6$	$19.9\pm0.5 \ddagger$	$19.6 \pm 1.0$	$20.0\pm1.3$	
Liver, %BW	$2.96\pm0.05$	$3.19\pm0.06 \ddagger$	$3.63 \pm 0.12$ ***	$3.83 \pm 0.19 **$	
Small intestine, g	$11.2\pm0.3$	$12.0\pm0.2$	$12.6\pm0.7$	$11.2\pm0.8$	
Small intestine, % BW	$1.84\pm0.03$	$1.93 \pm 0.04$	$2.39 \pm 0.22^{***}$	$2.13\pm0.10$	
Colon, g	$2.62\pm0.07$	$2.76\pm0.06$	$2.94 \pm 0.09^{*}$	$2.53\pm0.23$	
Colon, % BW	$0.434\pm0.008$	$0.444\pm0.011$	$0.551 \pm 0.024$ ***	$0.486 \pm 0.038$	

<sup>\*</sup> Data are means  $\pm$  SEM. † different from NI-Ala P < 0.03. \*, \*\*, \*\*\* different from corresponding NI group P < 0.05, P < 0.01, P < 0.001, respectively.







Ala: combined NI-Ala plus LGI-Ala groups, Cys: combined NI-Cys plus LGI-Cys groups.

**Fig. 3.** Effect of cysteine fortification on plasma non-protein cysteine concentration in old rats being non-inflamed or low-grade inflamed at baseline.



Bars are means  $\pm$  SEM. Panel A, upper SEM stand for total cysteine, lower SEM for free cysteine or proteinlinked cysteine. Symbols on the bars illustrate significant difference for free cysteine or protein-linked cysteine, symbols above the bars for total (free plus protein-linked) cysteine. \*, \*\* different from corresponding NI group P < 0.04 and P < 0.0007, respectively. † different from corresponding Ala group P < 0.006.

Comment citer ce document : Vidal, K., Breuille, D., Serrant, P., Denis, P., Glomot, F., Bechereau, F., Papet, I. (2014). Long-term cysteine fortification impacts cysteine/glutathione homeostasis and food intake in ageing rats. European Journal of Nutrition, 53 (3), 963 - 971., DOI : 10.1007/s00394-013-0600-0

**Fig. 4.** Effect of cysteine fortification on liver non-protein cysteine and glutathione concentrations and on  $\gamma$ -glutamylcysteine synthetase ( $\gamma$ -GCS) activity in old rats being non-inflamed or low-grade inflamed at baseline.



Bars are means  $\pm$  SEM. Panel A, upper SEM stand for total cysteine, lower SEM for free cysteine or proteinlinked cysteine. Symbols on the bars illustrate significant difference for free cysteine. \* different from corresponding NI group P < 0.05. †, †† different from corresponding Ala group P < 0.02 and P < 0.0004, respectively.

**Fig. 5.** Effect of cysteine fortification on small intestine non-protein cysteine and glutathione concentrations in old rats being non-inflamed or low-grade inflamed at baseline.



Bars are means  $\pm$  SEM. Panel A, upper SEM stand for total cysteine, lower SEM for free cysteine or proteinlinked cysteine. Symbols on the bars illustrate significant difference for free cysteine. \* different from corresponding NI group P < 0.04. †, †† different from corresponding Ala group P < 0.03 and P < 0.0001, respectively.



**Fig. 6.** Effect of cysteine fortification on plasma acute phase protein kinetics in ageing rats being non-inflamed or low-grade inflamed at baseline.

Bars are means  $\pm$  SEM. <sup>a, b, c, d</sup> labelled bars within a group without a common letter differ, P < 0.05. \* different from the same time point of the corresponding NI group P < 0.03.